PAR-25-266 newborn screening R21 eligibility Guide
Updated 5 official sources
Quick Answer: PAR-25-266 is an active NIH R21 for exploratory newborn screening and therapy research.
Full answer and how we checked it
It is clinical trial optional, lists October 16, 2026 as the next new-application date (November 16, 2026 for resubmissions), fits pilot-stage projects, and should be compared with the companion PAR-25-265 R01 before the team writes aims. The 2026 decision turns on 7 checks.
Who this is for: Newborn screening researchers, pediatric genetics teams, assay teams, therapy-development groups, state newborn-screening partners, and sponsored-research offices deciding whether the exploratory R21 path fits.
Data note: This guide uses NIH PAR-25-266, companion NIH PAR-25-265 R01, Grants.gov listing 357487, and USAspending FY2024 obligations, checked again on October 9, 2026.
In this guide
- October 2026 Source Check
- 6 PAR-25-266 Eligibility Stop Checks
- 5 Funding, Timing, and Mechanism Rules
- 5 R21 Versus R01 Route Choices
- What NIH Doesn't Tell You
- 7 Evidence Assets That Make This R21 Stronger
- 21-Day R21 Routing Plan
- 6 Reviewer-Risk Signals to Fix
- 7 Source-Backed Signals From PAR-25-266
- 5 Applicant Types and Best Next Move
- 7 Route Checks
- Sources
PAR-25-266 is not a smaller version of every newborn screening R01. According to NIH PAR-25-266 (opens in a new tab), the R21 route supports exploratory or developmental work that can break new direction, extend prior discoveries, or generate pilot data before a larger study.
A common mistake here: teams use the R21 because it feels easier, even when the project is already an R01, or they use the R01 because the topic feels important, even when the evidence base is still thin. The strongest route is the one that matches readiness.
Use this guide with the live NIH Newborn Screening R21 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, NIH Newborn Screening and Therapies R01 guide, what is a NOFO, and the Grantsights grant database.
October 2026 Source Check
According to NIH in PAR-25-266 (opens in a new tab), this R21 remains active. The June 16 and July 16, 2026 dates have passed. The next new-application date is October 16, 2026 and the next resubmission date is November 16, 2026, followed by February 16 and March 16, 2027. Submissions are due by 5 p.m. local time, and the NOFO expires November 17, 2027. NIH lists the clinical-trial status as optional and caps the two-year direct-cost budget at $275,000, with no more than $200,000 requested in any single year.
According to NIH in PAR-25-265 (opens in a new tab), the companion R01 is the longer-route option for established projects, while the R21 is for exploratory, pilot, feasibility, or early decision data. Settle that distinction before anyone drafts aims.
| October 9 check | Current source read | Applicant action |
|---|---|---|
| Status | Active through November 17, 2027 | Use the current NIH due-date table |
| Next new date | October 16, 2026 | Choose February 16, 2027 if access proof isn't ready |
| Trial status | Optional | Classify the project before the first draft |
| Budget | $275,000 total direct-cost cap | Keep year-one costs at or below $200,000 |
| Companion route | PAR-25-265 R01 | Use R01 if the work is already mature |
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
6 PAR-25-266 Eligibility Stop Checks
6 stop checks decide whether this R21 fits. The project should be tied to newborn screening, early detection, therapy timing, assay feasibility, or a screenable disorder where pilot work can change the next study.
| Stop check | Strong R21 signal | Red flag |
|---|---|---|
| Screening fit | Condition is in or near newborn screening use | General pediatric disorder without screening path |
| Mechanism scale | Pilot or feasibility work is the point | Full multi-year R01 is already justified |
| Data need | Project can generate decision data | Project only repeats known evidence |
| Trial status | Clinical-trial decision is explicit | Trial package is uncertain |
| Partner access | Sample, lab, or follow-up access is credible | Access depends on later promises |
| Next route | R21 can lead to R01 or clearer path | No next-step logic |
Don't use the R21 as a weak R01. Use it when the main question is feasibility, assay performance, therapy-readiness, sample access, or whether an early-detection route is worth a larger study.
5 Funding, Timing, and Mechanism Rules
5 public rules should appear in the first routing memo. According to NIH, PAR-25-266 is an R21 exploratory/developmental grant and is clinical trial optional. Grantsights records the live program deadline as November 16, 2027.
| Rule | Source-backed read |
|---|---|
| Funding number | PAR-25-266 |
| Mechanism | R21 exploratory/developmental research grant |
| Clinical trial status | Optional |
| Companion route | PAR-25-265 R01 |
| Live Grantsights deadline | November 16, 2027 |
According to NIH, the companion PAR-25-265 R01 is the larger route for projects that already justify multi-year R01 scope. According to USAspending.gov (opens in a new tab) data, assistance listing 93.865 had about $1.24B in FY2024 obligations across 5,330 awards active that year.
5 R21 Versus R01 Route Choices
5 route choices matter before the aims page. PAR-25-266 fits exploratory work. PAR-25-265 fits larger projects with enough evidence and operational capacity for R01 scope.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-266 R21 | Assay, therapy, sample, or follow-up feasibility is being tested | R21 scale fits |
| PAR-25-265 R01 | Evidence base supports a larger study | R01 scale fits |
| Parent R21 | Newborn screening is adjacent but not central | Broader route may fit |
| SBIR/STTR | Company-led product path is central | Small-business route may fit |
| Foundation or pilot funds | The project needs early prep before NIH | Prep funding may come first |
The honest answer is that many teams should start here, but not all. If the idea needs a state lab workflow test, assay validation, or therapy-readiness data, the R21 is usually better than a stretched R01.
What NIH Doesn't Tell You
4 hidden readiness questions decide whether this belongs under PAR-25-266. NIH gives the rule source, but it does not decide whether the project is exploratory in the right way.
First, NIH does not make a broad genetics project a newborn screening project. The application should explain how early detection changes testing, treatment, follow-up, or outcome interpretation.
Second, NIH does not make R21 a low-effort route. Reviewers still expect a tight hypothesis, defined methods, feasible milestones, and a credible next step.
Third, NIH does not make clinical-trial optional simple. If the project assigns an intervention to study a health outcome, the clinical-trial classification and forms need to match that choice from day 1.
Fourth, NIH does not create partner access. State newborn screening programs, specimen flows, confirmatory testing, clinical follow-up, and family data require early agreements.
7 Evidence Assets That Make This R21 Stronger
7 evidence assets help the R21 stand out. The strongest application shows exactly what uncertainty the R21 will resolve.
First, define the screenable condition and why early detection matters. A disease can be serious without fitting this route. The screening or early-treatment path has to be clear.
Second, name the feasibility question. According to NIH, example R21 work can include pilot testing of screening technologies or approaches, including other sample types such as urine, saliva, or stool. The application should say what will be known at the end of the R21 that is not known now.
Third, show why the sample or data plan is real. For example, a team that already has a state lab agreement, de-identified dried blood spot access, and a follow-up clinic can make a stronger case than a team that says access will be arranged later.
Fourth, connect therapy work to the screening window. If the therapy question has no real dependence on early detection, another route may fit better.
Fifth, include population and assay-performance logic. According to NIH, pilot tests should address recruitment of diverse groups when relevant and explain how screening assay performance may vary across populations.
Sixth, define success criteria. The R21 should have decision thresholds: assay sensitivity, specificity, feasibility, safety signal, follow-up completeness, or data quality.
Seventh, make the R01 bridge explicit. Reviewers should be able to see how the R21 produces data for PAR-25-265, a parent R01, or a different next step.
21-Day R21 Routing Plan
21 days is enough to decide whether the team should draft. Days 1 through 3 should confirm source status, deadline, clinical-trial status, and the companion R01 comparison.
Days 4 through 7 should test screening fit. The team should explain the condition, screening pathway, early-treatment window, and why this is not just general rare-disease work.
Days 8 through 12 should build feasibility proof. That includes sample access, state lab role, assay plan, data quality, therapy-readiness, and follow-up logic.
Days 13 through 16 should write the R21 milestone table. Reviewers need to know what success looks like after 2 years.
Days 17 through 21 should run submission checks, including clinical-trial forms, human-subjects records, budget, and program staff questions.
6 Reviewer-Risk Signals to Fix
6 risk signals should be fixed before submission. First, the aims should not read like a broad R01 with smaller budget language.
Second, the application should not confuse early-stage feasibility with weak design. R21 work can be exploratory and still rigorous.
Third, the clinical-trial status should be clear. Trial ambiguity can hurt the application before review.
Fourth, partner roles should be specific. A letter from a lab or clinic is not enough if the work depends on specimen flow or follow-up.
Fifth, the application should not overclaim state screening adoption. The R21 should prove a step toward adoption, not promise adoption before evidence exists.
Sixth, the next-step logic should be visible. Make the final paragraph of the strategy explain what R01, R21, SBIR/STTR, or implementation route comes after the pilot.
7 Source-Backed Signals From PAR-25-266
7 signals from NIH should shape the page and the applicant's internal memo. The first is that this is an R21, so the application should be built around exploratory value rather than a full program of work.
The second is clinical-trial optional status. That does not mean the applicant can decide late. The team should run NIH's clinical-trial questions before the first draft and should keep the classification consistent across the project summary, research strategy, human-subjects forms, and budget.
The third signal is the relationship to newborn screening practice. NIH describes work tied to screening approaches, technologies, therapies, and screenable disorders. That means a proposal about a rare condition should still explain how the research connects to newborn identification, early diagnosis, treatment timing, or follow-up.
The fourth signal is the companion R01. PAR-25-265 is not just a related link. It is the main comparison route. A useful exercise is a 2-column answer: what the R21 can prove in 2 years and what would justify an R01 later.
The fifth signal is assay or approach readiness. An R21 can test new sample types, use known tools in a different screening context, or develop early evidence for therapy timing. The applicant should still show why the work can be completed inside R21 scope.
The sixth signal is population and implementation awareness. A screening tool can fail if it performs unevenly across groups or cannot fit real-world newborn-screening workflows. The strongest R21s name that risk early.
The seventh signal is end-state clarity. At the end of the award, reviewers should be able to see whether the next move is a companion R01, a parent R01, a small-business route, a clinical study, or a decision to stop.
5 Applicant Types and Best Next Move
5 applicant types commonly ask about PAR-25-266, and each should leave the page with a different next move.
| Applicant type | Best next move | Why |
|---|---|---|
| Assay feasibility team | Build R21 milestone table | Pilot proof fits |
| Therapy-readiness team | Confirm early-detection link | Therapy must connect to screening |
| State screening partner | Define specimen and follow-up role | Workflow access matters |
| R01-ready research team | Compare PAR-25-265 | R21 may be too small |
| Company-led product team | Compare SBIR/STTR | Product path may differ |
The best answer is: use PAR-25-266 when the project is newborn-screening connected, exploratory, feasible within R21 scope, and ready to produce decision data for the next route.
7 Route Checks
Checked on October 9, 2026 against PAR-25-266 (opens in a new tab), PAR-25-265 (opens in a new tab), the Grants.gov listing (opens in a new tab), Grants.gov (opens in a new tab), and USASpending.gov (opens in a new tab).
| Check | What to confirm |
|---|---|
| Eligibility | The applicant, institution, and route rules for PAR-25-266 newborn screening R21 eligibility. |
| Source status | The official listing, notices, due date, and expiration status. |
| Budget | The $275,000 two-year direct-cost cap and the $200,000 single-year limit. |
| Evidence | The data, preliminary work, partner role, or implementation proof needed. |
| Bad fit | Whether the project belongs in a nearby NIH or federal route instead. |
| Review criteria | How the first page ties to significance, approach, team, environment, and source-specific criteria. |
| Next action | Whether to draft, ask the NIH program contact, or redirect. |
Final public checklist
- Confirm whether R21 is the right route or whether a nearby program fits better.
- Check budget, partner, match, or data-readiness constraints.
Sources
4 sources anchor this guide: the NIH R21 NOFO, the companion NIH R01 NOFO, the federal listing, and the Grantsights public database record.
- NIH PAR-25-266 R21 NOFO: grants.nih.gov (opens in a new tab)
- NIH PAR-25-265 companion R01: grants.nih.gov (opens in a new tab)
- Grants.gov listing 357487: grants.gov (opens in a new tab)
- Grantsights program record: NIH Newborn Screening R21
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open newborn screening R21 record
Check PAR-25-266, June and October 2026 dates, clinical-trial optional status, and R21 budget cap.
Compare newborn screening R01
Use when the project is mature enough for PAR-25-265 instead of exploratory R21 scope.
Compare NIH mechanisms
Use when the applicant is unsure whether R21, R01, SBIR/STTR, or another route fits.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-25-266 fund?
NIH says the R21 supports exploratory or developmental work tied to newborn screening approaches, therapies, and early detection for screenable disorders.
Are clinical trials allowed?
Yes. PAR-25-266 is clinical trial optional, so applicants must classify the project correctly.
What is the companion R01?
NIH lists PAR-25-265 as the companion R01 route for larger newborn screening and therapy projects.
What is the next 2026 deadline?
The June 16 and July 16, 2026 dates have passed. NIH lists October 16, 2026 for new applications and November 16, 2026 for resubmissions, then February 16 and March 16, 2027. The NOFO expires November 17, 2027.
Who should skip this route?
Skip it if the project is general pediatric genetics without a screening path, or if it is already mature enough for the R01.
Last updated October 10, 2026. Corrected October 9, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-265 Newborn Screening R01 Eligibility
PAR-25-265 newborn screening R01 guide for clinical-trial optional status, R01 versus R21 choice, system fit, therapy evidence, and budget checks.
Chemical Screening Optimization X01 Eligibility Guide
Chemical Screening and Optimization Facility X01 eligibility guide: NICHD services, no-award access, 12-month plans, and fit checks.
PAR-25-369 ELSI R21 eligibility Guide
PAR 25 369 ELSI R21 guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
maternal pediatric pharmacology R21 eligibility Guide
PAR 25 111 maternal pediatric guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-153 NCI Assay Screening R01 Eligibility Guide
NIH PAR-25-153 guide: NCI assay-development and screening R01 eligibility, clinical-trial-not-allowed fit, stages, and review checks.
PAR-25-357 NEI Secondary Data R21 Eligibility Guide
NIH PAR-25-357 guide: NEI secondary-data R21 eligibility, clinical-trial-not-allowed fit, data readiness, manuscript milestones, and review checks.